ONEPOINT-PROJECTS
onepoint PROJECTS, the leading provider of easy-to-use “real” project and portfolio management (PPM) software, has released version 16 of its web-based enterprise solution. With this major release, onepoint also launches a new “Strategic Management Option” that adds strategic planning and controlling functionality in the form of an optional module. Other key features include new report types such as chart and compound reports as well as further improvements to onepoint’s well-known two-way integration with JIRA.
Strategic Management Option
The new Strategic Management Option allows top management to communicate a strategic vision and break it down into several prioritized goals. Users can then plan initiatives to implement these goals and link these initiatives to one or more projects. However, onepoint’s approach to strategic management does not stop there, it also provides an integrated controlling component complete with an initiatives pipeline chart and aggregated progress information and status traffic lights.
“Today coming up with a good strategic plan is often not enough,“ said Gerald Aquila, founder & CEO of onepoint. “It is just as important to clearly communicate both your vision and your goals as well as to make sure that initiatives get off the ground and really add strategic value.”
JIRA Integration Improvements
As one of the first PPM vendors offering a JIRA integration, onepoint has since strived to continuously improve its bidirectional, real-time interface to Atlassian’s best-selling issue management application. For release 16 onepoint has completely rewritten the communication layer of its JIRA integration with the goal to further extend its leadership position.
Based on multiple years of experience and real-world customer feedback, this new generation of onepoint’s two-way JIRA synchronization features explicit planning of issue types, optional inclusion of subtasks into project plans, and simultaneous integration with multiple JIRA repositories – beside many minor improvements. The new communication layer also provides a solid and scalable foundation for further future improvements that are already on onepoint’s product roadmap.
Charts & Compound Reports
Another long-time functionality that onepoint’s customers love is its integrated report wizard providing end users with the ability to easily modify existing reports, as well as to create new ones. The new version improves the integrated reporting engine in two key areas: charts and compound reports. Report charts include WBS, schedule (GANTT), milestone-trend analysis and project pipeline charts, and can be used stand-alone or as parts of document-style reports. Compound reports provide the ability to bundle overview and detail reports for collection objects such as portfolios or pools into a single PDF document. A key example for a compound report is a portfolio status report with included individual status reports for each project.
Further improvements include a user interface refresh that especially focuses on making document-style areas such as project summaries, status reports, or meeting agendas better readable. In addition, skills management is no longer an optional module, but is now integrated into the base product.
onepoint PROJECTS 16 Group Server is available at no charge for up to 4 users. A free 30 day test drive of onepoint PROJECTS 16 Enterprise Server/Cloud with the complete functionality including optional modules can be requested via www.onepoint-projects.com . For more information about the new release or for inquiries about enterprise licensing and pricing, please contact our sales team via info@onepoint-projects.com or +43 316 267 267 0.
About onepoint PROJECTS
onepoint PROJECTS is the leading provider of integrated project and portfolio management solutions for innovative small and medium-sized project organizations. Unlike traditional PPM software, onepoint PROJECTS integrates formal, agile and JIRA projects into a single project portfolio and resource utilization database. Onepoint enables project-oriented organizations to increase project and portfolio transparency, shorten project lead times, automate best practices and optimize resource utilization. By building on open standards and technologies, providing both cloud-based/SaaS and on-premise installations and with its strategic focus on making PM systems easy to deploy, onepoint redefines ROI for project management solutions.
The company and product names mentioned are trademarks of their respective owners as long as they are registered.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170216005071/en/
Contact:
onepoint PROJECTS GmbH
Gerald Aquila
www.onepoint-projects.com
Phone:
+43-316-267-267-0
Fax: +43-316-267-267-99
Email: info@onepoint-projects.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release
The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev
7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release
MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t
First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release
Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom